The diagnosis and management of mild cognitive impairment: A clinical review

JAMA - Journal of the American Medical Association

Volumn 312, Issue 23, 2014, Pages 2551-2561

  Langa, Kenneth M ^a,b,c,d   Levine, Deborah A ^a,b,c  

^a UNIVERSITY OF MICHIGAN MEDICAL SCHOOL   (United States)

^b VETERANS AFFAIRS MEDICAL CENTER   (United States)

^c UNIVERSITY OF MICHIGAN   (United States)

^d UNIVERSITY OF MICHIGAN HEALTH SYSTEM   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

NOOTROPIC AGENT;

AEROBIC EXERCISE; AGING; BEHAVIOR THERAPY; CARDIOVASCULAR RISK; CAREGIVER; CEREBROVASCULAR ACCIDENT; CLINICAL EFFECTIVENESS; COGNITION; CONCEPTUAL FRAMEWORK; DEMENTIA; DEPRESSION; DISEASE COURSE; EARLY DIAGNOSIS; EVIDENCE BASED MEDICINE; FOLLOW UP; FUNCTIONAL STATUS; HIGH RISK POPULATION; HUMAN; LABORATORY TEST; MEDICAL CARE; MEDICAL EXAMINATION; MENTAL PERFORMANCE; META ANALYSIS (TOPIC); MILD COGNITIVE IMPAIRMENT; NEUROIMAGING; NEUROPSYCHOLOGICAL TEST; PATIENT ASSESSMENT; PATIENT CARE; PATIENT COUNSELING; PEER REVIEW; PHARMACEUTICAL CARE; POLYPHARMACY; POPULATION RESEARCH; POSITRON EMISSION TOMOGRAPHY; PRACTICE GUIDELINE; PREVALENCE; PROGNOSIS; REVIEW; RISK MANAGEMENT; RISK REDUCTION; SEX DIFFERENCE; SOCIAL INTERACTION; SYSTEMATIC REVIEW; AGED; CARDIOVASCULAR DISEASE; EXERCISE; FEMALE; MALE; PSYCHOLOGY; RISK FACTOR;

AGED; AGING; CARDIOVASCULAR DISEASES; DEMENTIA; DISEASE PROGRESSION; EXERCISE; FEMALE; HUMANS; MALE; MILD COGNITIVE IMPAIRMENT; PROGNOSIS; RISK FACTORS;

EID: 84919343493     PISSN: 00987484     EISSN: 15383598     Source Type: Journal    
DOI: 10.1001/jama.2014.13806     Document Type: Review

References (92)

1. McKhann GM, Knopman DS, Chertkow H, et al. The diagnosis of dementia due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 263-269.
2. AlbertMS, DeKosky ST, Dickson D, et al. The diagnosis of mild cognitive impairment due to Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 270-279.
3. Sperling RA, Aisen PS, Beckett LA, et al. Toward defining the preclinical stages of Alzheimer's disease: recommendations from the National Institute on Aging-Alzheimer's Association workgroups on diagnostic guidelines for Alzheimer's disease. Alzheimers Dement. 2011;7(3): 280-292.
4. Institute for Clinical and Economic Review. Diagnostic tests for Alzheimer's disease: defining evidence standards for insurance coverage of diagnostic tests for Alzheimer's Disease: 2012. http://www.icer-review.org/alzheimers/. Accessed August 8, 2014.
5. Centers for Medicare & Medicaid Services. Decision memo for beta amyloid positron emission tomography in dementia and neurodegenerative disease (CAG-00431N). http://www.cms.gov/medicare-coverage-database/details/nca-decision -memo.aspx?NCAId=265. Accessed August 8, 2014.
6. Petersen RC. Clinical practice: mild cognitive impairment.NEngl J Med. 2011;364(23):2227-2234.
7. Dubois B, Feldman HH, Jacova C, et al. Revising the definition of Alzheimer's disease. Lancet Neurol. 2010;9(11):1118-1127.
8. American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. Washington, DC: American Psychiatric Association; 2013.
9. Plassman BL, Langa KM, Fisher GG, et al. Prevalence of cognitive impairment without dementia in the United States. Ann Intern Med. 2008;148(6):427-434.
10. Matthews FE, Stephan BC, McKeith IG, et al. Two-year progression from mild cognitive impairment to dementia. J AmGeriatr Soc. 2008; 56(8):1424-1433.
11. Petersen RC, Roberts RO, Knopman DS, et al. Prevalence of mild cognitive impairment is higher in men. Neurology. 2010;75(10):889-897.
12. Yaffe K, Laffan AM, Harrison SL, et al. Sleep-disordered breathing, hypoxia, and risk of mild cognitive impairment and dementia in older women. JAMA. 2011;306(6):613-619.
13. Iwashyna TJ, Ely EW, Smith DM, Langa KM. Long-term cognitive impairment and functional disability among survivors of severe sepsis. JAMA. 2010;304(16):1787-1794.
14. McCarten JR. Clinical evaluation of early cognitive symptoms. Clin Geriatr Med. 2013;29(4): 791-807.
15. Holsinger T, Deveau J, Boustani M, Williams JW Jr. Does this patient have dementia? JAMA. 2007; 297(21):2391-2404.
16. Lin JS, O'Connor E, Rossom R, et al. Screening for Cognitive Impairment in Older Adults: An Evidence Update for the U.S. Preventive Services Task Force. Rockville, MD: Agency for Healthcare Research and Quality; 2013. Evidence Report 107. AHRQ Publication 14-05198-EF-1.
17. Nasreddine ZS, Phillips NA, Bedirian V, et al. The Montreal Cognitive Assessment, MoCA: a brief screening tool formild cognitive impairment. J Am Geriatr Soc. 2005;53(4):695-699.
18. Roalf DR, Moberg PJ, Xie SX,Wolk DA, Moelter ST, Arnold SE. Comparative accuracies of two common screening instruments for classification of Alzheimer's disease,mild cognitive impairment, and healthy aging. Alzheimers Dement. 2013;9(5): 529-537.
19. Jorm AF. A short form of the Informant Questionnaire on Cognitive Decline in the Elderly (IQCODE). Psychol Med. 1994;24(1):145-153.
20. Clark CM, Ewbank DC. Performance of the dementia severity rating scale. Alzheimer Dis Assoc Disord. 1996;10(1):31-39.
21. Galvin JE, Roe CM, Powlishta KK, et al. The AD8: a brief informant interview to detect dementia. Neurology. 2005;65(4):559-564.
22. Pfeffer RI, Kurosaki TT, Harrah CH Jr, Chance JM, Filos S. Measurement of functional activities in older adults in the community. J Gerontol. 1982;37 (3):323-329.
23. Brown PJ, Devanand DP, Liu X, Caccappolo E; Alzheimer's Disease Neuroimaging Initiative. Functional impairment in elderly patients with mild cognitive impairment and mild Alzheimer disease. Arch Gen Psychiatry. 2011;68(6):617-626.
24. Teng E, Becker BW,Woo E, Knopman DS, Cummings JL, Lu PH. Utility of the functional activities questionnaire for distinguishing mild cognitive impairment from verymild Alzheimer disease. Alzheimer Dis Assoc Disord. 2010;24(4): 348-353.
25. Widera E, Steenpass V, Marson D, Sudore R. Finances in the older patient with cognitive impairment. JAMA. 2011;305(7):698-706.
26. Steinman MA, Hanlon JT. Managing medications in clinically complex elders. JAMA. 2010;304(14):1592-1601.
27. Shumaker SA, Legault C, Kuller L, et al; Women's Health Initiative Memory Study. Conjugated equine estrogens and incidence of probable dementia and mild cognitive impairment in postmenopausal women. JAMA. 2004;291(24): 2947-2958.
28. Liu H, Gao S, Hall KS, et al. Optimal blood pressure for cognitive function: findings from an elderly African-American cohort study. J AmGeriatr Soc. 2013;61(6):875-881.
29. Yaffe K, Falvey CM, Hamilton N, et al. Association between hypoglycemia and dementia in a biracial cohort of older adults with diabetes mellitus. JAMA Intern Med. 2013;173(14):1300-1306.
30. Yesavage JA,Brink TL,Rose TL, et al. Development and validation of a geriatric depression screening scale. J Psychiatr Res. 1982- 1983;17(1):37-49.
31. Cummings JL, Mega M, Gray K, Rosenberg-Thompson S, Carusi DA, Gornbein J. The Neuropsychiatric Inventory: comprehensive assessment of psychopathology in dementia. Neurology. 1994;44(12):2308-2314.
32. Jack CR Jr,Wiste HJ, Vemuri P, et al; Alzheimer's Disease Neuroimaging Initiative. Brain beta-amyloid measures and magnetic resonance imaging atrophy both predict time-to-progression frommild cognitive impairment to Alzheimer's disease. Brain. 2010;133(11):3336-3348.
33. Jack CR Jr, Lowe VJ,Weigand SD, et al; Alzheimer's Disease Neuroimaging Initiative. Serial PIB and MRI in normal,mild cognitive impairment and Alzheimer's disease: implications for sequence of pathological events in Alzheimer's disease. Brain. 2009;132(Pt 5):1355-1365.
34. Jack CR Jr, Barkhof F, Bernstein MA, et al. Steps to standardization and validation of hippocampal volumetry as a biomarker in clinical trials and diagnostic criterion for Alzheimer's disease. Alzheimers Dement. 2011;7(4):474-485.e4.
35. RiesML, Carlsson CM, Rowley HA, et al. Magnetic resonance imaging characterization of brain structure and function inmild cognitive impairment. J AmGeriatr Soc. 2008;56(5):920-934.
36. Small GW, Bookheimer SY, Thompson PM, et al. Current and future uses of neuroimaging for cognitively impaired patients. Lancet Neurol. 2008; 7(2):161-172.
37. Clark CM, Schneider JA, Bedell BJ, et al. Use of florbetapir-PET for imaging beta-amyloid pathology. JAMA. 2011;305(3):275-283.
38. Johnson KA, Sperling RA, Gidicsin CM, et al; AV45-A11 study group. Florbetapir (F18-AV-45) PET to assess amyloid burden in Alzheimer's disease dementia,mild cognitive impairment, and normal aging. Alzheimers Dement. 2013;9(5)(suppl):S72-S83.
39. Clarfield AM. The decreasing prevalence of reversible dementias. Arch Intern Med. 2003;163 (18):2219-2229.
40. Mattsson N, Zetterberg H, Hansson O, et al. CSF biomarkers and incipient Alzheimer disease in patients with mild cognitive impairment. JAMA. 2009;302(4):385-393.
41. Petersen RC, Trojanowski JQ. Use of Alzheimer disease biomarkers. JAMA. 2009;302(4):436-437.
42. Salloway S, Ferris S, Kluger A, et al. Efficacy of donepezil inmild cognitive impairment. Neurology. 2004;63(4):651-657.
43. Petersen RC, Thomas RG, Grundman M, et al. Vitamin E and donepezil for the treatment of mild cognitive impairment. N Engl J Med. 2005;352(23): 2379-2388.
44. Doody RS, Ferris SH, Salloway S, et al. Donepezil treatment of patients with MCI: a 48-week randomized, placebo-controlled trial. Neurology. 2009;72(18):1555-1561.
45. Koontz J, Baskys A. Effects of galantamine on working memory and global functioning in patients with mild cognitive impairment. Am J Alzheimers Dis Other Demen. 2005;20(5):295-302.
46. Buschert VC, Friese U, Teipel SJ, et al. Effects of a newly developed cognitive intervention in amnestic mild cognitive impairment and mild Alzheimer's disease. J Alzheimers Dis. 2011;25(4): 679-694.
47. Barnes DE, Yaffe K, Belfor N, et al. Computer-based cognitive training for mild cognitive impairment. Alzheimer Dis Assoc Disord. 2009;23(3):205-210.
48. Barnes DE, Santos-ModesittW, Poelke G, et al. The Mental Activity and eXercise (MAX) trial: a randomized controlled trial to enhance cognitive function in older adults. JAMA Intern Med. 2013;173 (9):797-804.
49. Wolfs CA, Kessels A, Dirksen CD, Severens JL, Verhey FR. Integrated multidisciplinary diagnostic approach for dementia care. Br J Psychiatry. 2008; 192(4):300-305.
50. Joosten-Weyn Banningh LW, Prins JB, Vernooij-Dassen MJ,Wijnen HH, Olde Rikkert MG, Kessels RP. Group therapy for patients with mild cognitive impairment and their significant others. Gerontology. 2011;57(5):444-454.
51. Banningh LW, Vernooij-Dassen MJ, Vullings M, Prins JB, Rikkert MG, Kessels RP. Learning to live with a loved one with mild cognitive impairment. Am J Alzheimers Dis Other Demen. 2013;28(3):228-238.
52. Lautenschlager NT, Cox KL, Flicker L, et al. Effect of physical activity on cognitive function in older adults at risk for Alzheimer disease. JAMA. 2008;300(9):1027-1037.
53. Baker LD, Frank LL, Foster-Schubert K, et al. Effects of aerobic exercise onmild cognitive impairment. Arch Neurol. 2010;67(1):71-79.
54. Suzuki T, Shimada H, Makizako H, et al. Effects of multicomponent exercise on cognitive function in older adults with amnestic mild cognitive impairment. BMC Neurol. 2012;12:128.
55. Nagamatsu LS, Handy TC, Hsu CL, Voss M, Liu-Ambrose T. Resistance training promotes cognitive and functional brain plasticity in seniors with probablemild cognitive impairment. Arch Intern Med. 2012;172(8):666-668.
56. Russ TC, Morling JR. Cholinesterase inhibitors formild cognitive impairment. Cochrane Database Syst Rev. 2012;9:CD009132.
57. Snitz BE, O'Meara ES, Carlson MC, et al. Ginkgo biloba for preventing cognitive decline in older adults. JAMA. 2009;302(24):2663-2670.
58. Emmelot-Vonk MH, Verhaar HJ, Nakhai Pour HR, et al. Effect of testosterone supplementation on functional mobility, cognition, and other parameters in older men. JAMA. 2008;299(1):39-52.
59. Bosch J, Yusuf S, Pogue J, et al. Use of ramipril in preventing stroke. BMJ. 2002;324(7339):699-702.
60. Snowdon DA, Greiner LH, Mortimer JA, Riley KP, Greiner PA, MarkesberyWR. Brain infarction and the clinical expression of Alzheimer disease. JAMA. 1997;277(10):813-817.
61. Vermeer SE, Prins ND, den Heijer T, Hofman A, Koudstaal PJ, Breteler MM. Silent brain infarcts and the risk of dementia and cognitive decline. N Engl J Med. 2003;348(13):1215-1222.
62. Schneider JA, Arvanitakis Z, Leurgans SE, Bennett DA. The neuropathology of probable Alzheimer disease and mild cognitive impairment. Ann Neurol. 2009;66(2):200-208.
63. Meschia JF, Bushnell C, Boden-Albala B, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, Council on Functional Genomics and Translational Biology, and Council on Hypertension. Guidelines for the primary prevention of stroke: a statement for healthcare professionals from The American Heart Association/American Stroke Association. Stroke. 2014;45(12):3754-3832.
64. Kernan WN, Ovbiagele B, Black HR, et al; American Heart Association Stroke Council, Council on Cardiovascular and Stroke Nursing, Council on Clinical Cardiology, and Council on Peripheral Vascular Disease. Guidelines for the prevention of stroke in patients with stroke and transient ischemic attack: a guideline for healthcare professionals from the American Heart Association/American Stroke Association. Stroke. 2014;45(7):2160-2236.
65. Forette F, Seux ML, Staessen JA, et al. Prevention of dementia in randomised double-blind placebo-controlled Systolic Hypertension in Europe (Syst-Eur) trial. Lancet. 1998;352(9137):1347-1351.
66. Peters R, Beckett N, Forette F, et al. Incident dementia and blood pressure lowering in the Hypertension in the Very Elderly Trial cognitive function assessment (HYVET-COG). Lancet Neurol. 2008;7(8):683-689.
67. van Dijk EJ, Prins ND, Vrooman HA, Hofman A, Koudstaal PJ, Breteler MM. Progression of cerebral small vessel disease in relation to risk factors and cognitive consequences. Stroke. 2008;39(10):2712-2719.
68. White WB,Wolfson L,Wakefield DB, et al. Average daily blood pressure, not office blood pressure, is associated with progression of cerebrovascular disease and cognitive decline in older people. Circulation. 2011;124(21):2312-2319.
69. James PA, Oparil S, Carter BL, et al. 2014 Evidence-based guideline for the management of high blood pressure in adults: report from the panel members appointed to the Eighth Joint National Committee (JNC 8). JAMA. 2014;311(5):507-520.
70. Webb AJ, Fischer U, Mehta Z, Rothwell PM. Effects of antihypertensive-drug class on interindividual variation in blood pressure and risk of stroke. Lancet. 2010;375(9718):906-915.
71. Sabayan B,Wijsman LW, Foster-Dingley JC, et al. Association of visit-to-visit variability in blood pressure with cognitive function in old age. BMJ. 2013;347:f4600.
72. Gao S, Hendrie HC,Wang C, et al. Redefined blood pressure variability measure and its association with mortality in elderly primary care patients. Hypertension. 2014;64(1):45-52.
73. Montero-OdassoM, Verghese J, Beauchet O, Hausdorff JM. Gait and cognition. J AmGeriatr Soc. 2012;60(11):2127-2136.
74. Lin FR, Yaffe K, Xia J, et al. Hearing loss and cognitive decline in older adults. JAMA Intern Med. 2013;173(4):293-299.
75. RogersMA, Langa KM. Untreated poor vision: a contributing factor to late-life dementia. Am J Epidemiol. 2010;171(6):728-735.
76. Cai X, Campbell N, Khan B, Callahan C, Boustani M. Long-term anticholinergic use and the aging brain. Alzheimers Dement. 2013;9(4):377-385.
77. Feart C, Samieri C, Rondeau V, et al. Adherence to a Mediterranean diet, cognitive decline, and risk of dementia. JAMA. 2009;302(6):638-648.
78. Ertel KA, Glymour MM, Berkman LF. Effects of social integration on preserving memory function in a nationally representative US elderly population. Am J Public Health. 2008;98(7):1215-1220.
79. Martin M, Clare L, Altgassen AM, Cameron MH, Zehnder F. Cognition-based interventions for healthy older people and people with mild cognitive impairment. Cochrane Database Syst Rev. 2011;(1): CD006220.
80. Carr DB, Ott BR. The older adult driver with cognitive impairment: "It's a very frustrating life." JAMA. 2010;303(16):1632-1641.
81. RapoportMJ, Naglie G, Herrmann N, et al. Developing physician consensus on the reporting of patients with mild cognitive impairment and mild dementia to transportation authorities in a region with mandatory reporting legislation. Am J Geriatr Psychiatry. 2013;pii: S1064-7481(13):00422-00423.
82. Petersen RC, Stevens JC, GanguliM, et al. Practice parameter: early detection of dementia: mild cognitive impairment (an evidence-based review). Neurology. 2001;56(9):1133-1142.
83. Farias ST, Mungas D, Reed BR, Harvey D, DeCarli C. Progression of mild cognitive impairment to dementia in clinic- vs community-based cohorts. Arch Neurol. 2009;66(9):1151-1157.
84. Petersen RC, Aisen P, Boeve BF, et al. Mild cognitive impairment due to Alzheimer disease in the community. Ann Neurol. 2013;74(2):199-208.
85. Mitchell AJ, Shiri-Feshki M. Rate of progression of mild cognitive impairment to dementia. Acta Psychiatr Scand. 2009;119(4):252-265.
86. Koepsell TD, Monsell SE. Reversion frommild cognitive impairment to normal or near-normal cognition. Neurology. 2012;79(15):1591-1598.
87. Campbell NL, Unverzagt F, LaMantia MA, Khan BA, Boustani MA. Risk factors for the progression of mild cognitive impairment to dementia. Clin Geriatr Med. 2013;29(4):873-893.
88. Elias-Sonnenschein LS, ViechtbauerW, Ramakers IH, Verhey FR, Visser PJ. Predictive value of APOE-ε4 allele for progression from MCI to AD-type dementia. J Neurol Neurosurg Psychiatry. 2011;82(10):1149-1156.
89. Jicha GA, Parisi JE, Dickson DW, et al. Neuropathologic outcome of mild cognitive impairment following progression to clinical dementia. Arch Neurol. 2006;63(5):674-681.
90. Brayne C, Davis D. Making Alzheimer's and dementia research fit for populations. Lancet. 2012; 380(9851):1441-1443.
91. Wikler EM, Blendon RJ, Benson JM.Would you want to know? Public attitudes on early diagnostic testing for Alzheimer's disease. Alzheimers Res Ther. 2013;5(5):43.
92. Le Couteur DG, Doust J, Creasey H, Brayne C. Political drive to screen for pre-dementia: not evidence based and ignores the harms of diagnosis. BMJ. 2013;347:f5125.